Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

Rhea-AI Summary

Verana Health and Guardant Health (Nasdaq: GH) announced a March 24, 2026 partnership to combine Verana's curated, therapeutic-specific EHR datasets with Guardant's clinicogenomic testing data to accelerate oncology drug development and improve real-world treatment insights.

The merged Verana/COTA portfolio expands reach to >95 million patients, >20,000 clinicians, and accessible oncology patients to over 10 million.

Positive

• Combined data reach of over 95 million patients
• Accessible oncology cohort increased to over 10 million patients
• Services cover 17 of the top 20 global biopharma companies
• Expanded AMCs network: access to more than 30 academic medical centers

Negative

• None.

Argus Mar 24 session

-1.61% close to close Open Argus

Details

News Market Reaction – GH

On Mar 24, the day this news came out, GH closed 1.61% below the previous close.

Data tracked by StockTitan Argus for the Mar 24 session.

Key Figures

Global biopharma clients: 17 of top 20 Patient records: over 95 million patients Contributing clinicians: over 20,000 clinicians +5 more

Global biopharma clients

17 of top 20

Combined company biopharma customer base

Patient records

over 95 million patients

Access across Verana Health networks

Contributing clinicians

over 20,000 clinicians

Providers feeding into Verana datasets

Academic Medical Centers

more than 30 centers

Expanded network access after merger

Oncology patients

over 10 million

Accessible oncology patients via combined data

AUA booth

Booth 2469

Verana presence at AUA 2026 Annual Meeting

Webinar date

Tuesday, April 14

Precision oncology webinar referenced in article

Event year

2026

American Urological Association Annual Meeting

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   AACR data previews

   24h Move

   -1.7%

   Planned presentation of 28 abstracts highlighting advances in tumor typing and testing.

2. Mar 16

   Asia Shield launch

   24h Move

   +1.8%

   Partnership with Manulife to offer Shield multi-cancer detection in Asian markets.

3. Mar 13

   CRC survey results

   24h Move

   +1.8%

   Harris Poll showing strong support for blood-based colorectal cancer screening access.

4. Mar 10

   Quest distribution deal

   24h Move

   -0.8%

   Shield test made orderable via Quest’s national network to broad clinician base.

5. Mar 04

   Screening tour launch

   24h Move

   -0.3%

   Nationwide mobile tour to expand access to Shield colorectal cancer blood testing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

real-world data, ehr, clinicogenomic, molecular biomarkers, +3 more

7 terms

real-world data medical

"revolutionizing patient care and clinical research through real-world data (RWD)"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

ehr technical

"regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies"

EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.

clinicogenomic medical

"Guardant's clinicogenomic testing data to accelerate the development of new therapies"

Clinicogenomic refers to combining a patient's clinical information (symptoms, medical history, outcomes) with their genomic or genetic data to understand disease behavior and predict who will respond to which treatments. For investors, this matters because clinicogenomic insights can make drug development and clinical trials more efficient, reveal opportunities for targeted therapies or diagnostics, and reduce risk—like matching the right key to the right lock to improve the odds of success and commercial value.

molecular biomarkers medical

"validate correlations between molecular biomarkers, treatment decisions and clinical outcomes"

Molecular biomarkers are measurable molecules in blood, tissue or other samples that act like dashboard lights for the body, signaling the presence, stage or likely response to a disease or treatment. Investors care because these markers guide drug and diagnostic development, influence clinical trial success, regulatory approval pathways and market adoption, and can shorten timelines or raise commercial value when they reliably predict outcomes.

tumor mutational burden (tmb) medical

"validate biomarker measures (e.g., Tumor Mutational Burden (TMB)) using real-world response"

Tumor mutational burden (TMB) measures how many genetic changes (mutations) are present in a cancer’s DNA; think of it like counting the number of 'passport stamps' in a tumor’s genome. Higher TMB can make a tumor more visible to the immune system and is often used to predict whether immune-based therapies will work, so investors watch TMB data because it can affect a drug’s trial success, approval chances, and market potential.

biomarker medical

"discovery of new biomarker-based therapies for patients and make the drug development"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

fda regulatory

"top-tier partner for organizations working closely with the FDA."

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development 

SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care.

Using the extensive datasets the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes. For example, from an urology perspective novel use cases of combining genomics data with NMIBC EHR curated data could enhance understanding the patient journey in risk refinement beyond stage/grade, lead to better treatment selection insights (i.e., who benefits from Bacillus Calmette-Guerin (BCG), the standard of care for most Non-muscle invasive bladder cancer (NMIBC) patients vs. who needs earlier escalation, and validate biomarker measures (e.g., Tumor Mutational Burden (TMB)) using real-world response and outcome endpoints. Ultimately, the combination provides greater insights into existing research data with comprehensive real-world data—including critical longitudinal serial testing information—needed to optimize drug development and accelerate programs that treat cancer across diverse patient populations.

"Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient," said Sujay Jadhav, CEO of Verana Health. "Connecting Guardant's data to Verana Health's in-depth, real-world oncology, and urology data assets will also allow researchers to anticipate treatment responses and accelerate drug development for existing and new population segments."

"The real-world data partnership with Verana marks another significant milestone in our mission to advance novel therapies, in particular cancer, with data," said Craig Eagle, MD, Guardant Health chief medical officer. "Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical as well."

Guardant's extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while Verana Health's highly curated data tracks a patient's complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens Verana Health's data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data set with considerable patient overlap for enhanced clinical insights.

The recent merger of COTA with Verana Health has expanded the therapeutic footprint. With its focus on real-world patient data in oncology, COTA complements Verana Health data and technology offerings across ophthalmology, urology, and neurology. The company is an exclusive partner of the American Academy of Ophthalmology IRIS^® Registry (Intelligent Research in Sight) and the American Urological Association (AUA) Quality (AQUA)^® Registry. The combined portfolio supports life sciences companies with clinical trials, drug submissions, health economics research, market-access strategies, and clinicians with MIPS advisory services.

The merger strengthens Verana Health's relationships within the biopharma industry. The combined company will serve 17 of the top 20 global biopharma companies, with access to over 95 million patients, over 20,000 contributing clinicians, including expanded network access to more than 30 Academic Medical Centers, increasing accessible oncology patients to over 10 million.

Additionally, the companies' combined regulatory expertise positions them as a top-tier partner for organizations working closely with the FDA. Together, the joint entity represents a powerhouse of RWD offerings and clinical trial solutions for accelerating results in the life sciences industry.

Join us on an upcoming webinar Precision Oncology Has a Blind Spot—and It's Not Genomics on Tuesday, April 14 to learn more. Register now.

Researchers interested in more information can schedule a time to meet Verana Health representatives during the American Urological Association (AUA) 2026 Annual Meeting (Booth 2469) or post-event.

About Verana Health

Verana Health, Inc.^® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html

SOURCE Verana Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Verana and Guardant Health partnership announced March 24, 2026 mean for GH shareholders?

It expands Guardant's clinicogenomic data utility and potential market demand for GH's testing services. According to Guardant Health, the deal links tumor biology data to curated EHRs to accelerate biomarker-driven drug development and may improve Guardant's commercial relevance to biopharma researchers.

How large is the combined Verana/COTA and Guardant data asset referenced in the March 24, 2026 announcement?

The collaboration cites access to over 95 million patients and more than 20,000 clinicians. According to Verana Health, the merged portfolio increases accessible oncology patients to over 10 million with expanded academic medical center coverage.

Which cancer types will the Verana and Guardant Health collaboration prioritize for research using combined datasets?

The partnership highlights expanded breadth into solid tumors, notably lung, breast, and colorectal cancers. According to Verana Health, combining clinicogenomic and curated EHR data aims to yield deeper insights across these tumor types and related treatment outcomes.

Will the Verana and Guardant Health partnership affect drug development timelines for biomarker therapies?

The companies say the combined real-world and genomic data can expedite hypothesis testing and validation of biomarkers. According to both firms, connecting tumor biology with longitudinal outcomes may streamline target selection and improve trial design efficiency.

How does the March 24, 2026 merger of COTA with Verana Health change the combined company's client reach?

The merger broadened therapeutic coverage and client access, enabling service to 17 of the top 20 biopharma companies. According to Verana Health, the combined offerings support clinical trials, submissions, HEOR, and market-access strategies.

Are there upcoming events where investors can learn more about the Verana–Guardant collaboration and GH implications?

Yes; a webinar titled "Precision Oncology Has a Blind Spot—and It's Not Genomics" is scheduled for April 14, 2026, and Verana will attend AUA 2026. According to Verana Health, investors and researchers can register and meet company representatives at Booth 2469.